The Limbic

Prof. David Joske on why complementary therapies have a role to play in modern cancer care

The haematology community needs to 'up its humanity' and do more to meet the broader range of needs of people with blood cancer, says an eminent speaker at Blood 2019 in Perth. Delivering the Carl de Gruchy Oration, self-declared ‘lymphomaniac’ Professor...

The haematology community needs to 'up its humanity' and do more to meet the broader range of needs of people...

Blood cancers

Multiple myeloma patients missing out on optimal therapy

Australian multiple myeloma patients are failing to advance to subsequent lines of therapy and are therefore missing out on newer therapies, a registry study finds. Presenting the findings at Blood 2019, Dr Jessie Zhao from Dorevitch Pathology, in Heidelberg, Melbourne, said...

Australian multiple myeloma patients are failing to advance to subsequent lines of therapy and are therefore missing out on newer...

Coagulation

DOACs could become standard of care in cancer related VTE: expert

Emerging evidence suggests that DOACs are likely to replace low molecular weight heparin as the standard of care for cancer-related thrombosis, with the possible exception of patients with GI cancer, an expert says. Speaking at Blood 2019, Professor John Eikelboom from...

Emerging evidence suggests that DOACs are likely to replace low molecular weight heparin as the standard of care for cancer-related...